
New FTI Consulting Survey Reveals Mounting Challenges Continue for U.S. Hospitals
WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced findings from its annual Hospital Operations Outlook Survey of more than 200 senior executives across all types of hospitals. The survey found rising costs, patient wait times, workforce challenges and persistent cybersecurity threats are among the top issues highlighted by hospital leaders.
These issues — bundled with an increasingly complex operating environment shaped by regulatory changes, such as potential Medicaid cuts from the federal government, inflationary pressures and growing patient demand — make adaptability and nimbleness in an organization's ability to quickly respond to these challenges critical. Moreover, clear and strategic communications to stakeholders about the mounting pressures and plans to address them are more important than ever to maintain support inside and outside the hospital.
To protect their reputation and fulfill their mission, hospital leaders must stay closely connected with stakeholders while embracing value-based care, digital innovation, workforce investment and proactive cybersecurity risk mitigation as part of a broader strategic plan.
'Healthcare leaders are at a crossroads, juggling financial pressures with the need to deliver high-quality care, support hospital staff and improve patient outcomes,' said Lauren Crawford Shaver, Head of Healthcare & Life Sciences for the Americas within the Strategic Communications segment at FTI Consulting. 'At the same time, adaptation to the digital era demands investment in modern infrastructure, robust cybersecurity and AI-driven efficiencies. And with the regulatory landscape in constant flux, staying ahead requires more than strategy and vision. It takes agility to lead in a world that won't stand still.'
Key findings from the survey:
Workforce management costs dominate financial concerns, with 34% of respondents citing recruitment, retention and agency staffing expenses as critical stressors.
Cybersecurity threats remain top of mind, identified by half of respondents (50%) as their top digital concern, driven primarily by the concern for potential data breaches and operational disruptions.
Workforce shortages persist, with 48% of executives feeling their hospitals are unprepared for current patient volumes, particularly in specialist (49%) and nursing roles (46%).
Hospitals continue shifting toward value-based care, with hospitals reporting 42% of patient populations now participate in value-based care models due to better care coordination and improved patient outcomes as reported by 91% of respondents.
'Hospital executives are seeing promising, sustainable results when it comes to value-based care. This model is increasingly viewed as a smart, strategic approach in today's evolving healthcare environment given ongoing challenges such as market pressures and a shifting regulatory landscape,' said Paul Dioguardi, a Managing Director in FTI Consulting's Healthcare Risk Management & Advisory practice.
'In today's fast-evolving healthcare landscape, hospital leaders must make decisions that build resilient organizations,' said Rebecca Ayer Pitt, a Managing Director in FTI Consulting's Corporate Reputation practice within the Strategic Communications segment. 'This means investing in their workforce and value-based care as well as strengthening digital and cybersecurity capabilities. Most importantly, communicating proactively and transparently about strategic decisions and actions will build and maintain stakeholder confidence and support. In doing so, health systems will be better positioned to face the demands of the current healthcare environment without losing sight of what matters most — delivering exceptional care and patient outcomes.'
About the Survey
This research was conducted online by FTI Consulting's Strategic Communications segment between March 3, 2025 and March 12, 2025, with more than 200 senior executives across all types of hospitals and 17 mid-level leaders of academic hospitals. Overall, 60 respondents represent academic hospitals, 96 are part of a health system and 47 are hospitals not affiliated with health systems.
'FTI Consulting's Hospital Operations Outlook Survey offers healthcare leaders valuable insights into the headwinds and tailwinds being experienced by hospital and health system executives,' said James Condon, a Managing Director and Head of Research for the Americas in the Strategic Communications segment at FTI Consulting. 'The survey is designed to provide a holistic perspective on current industry pressures, and highlights innovative, forward-thinking, technology-driven solutions that are being leveraged by hospitals to adapt to and overcome these hardships.'
The full survey report is available here.
About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 33 countries and territories as of March 31, 2025. In certain jurisdictions, FTI Consulting's services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.70 billion in revenues during fiscal year 2024. More information can be found at www.fticonsulting.com.
FTI Consulting, Inc.
555 12 th Street NW
Washington, DC 20004
+1.202.312.9100
Investor Contact:
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com
Media Contact:
Matthew Bashalany
+1.617.897.1545
matthew.bashalany@fticonsulting.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
an hour ago
- National Post
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
Article content GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood within just 35 minutes. Article content sTREM2 is a promising biomarker of microglial activation, offering researchers insights into neuroinflammation linked to Alzheimer's and other neurodegenerative diseases. sTREM2 can be valuable for capturing the dynamics of inflammatory responses or for monitoring inflammatory modulators. This test complements Fujirebio's growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company's leading position in advancing neuro biomarker research tools and diagnostics. Article content Article content 'By adding sTREM2 to our neuro portfolio, we're enabling a more comprehensive view of neurological disease mechanisms,' Article content said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. 'sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation – offering a more complete picture of the disease on a single platform.' Article content The new test allows researchers and clinical research professionals to further study and understand the potential clinical utility of this promising microglial biomarker. The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements. Article content About Fujirebio Article content Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Article content Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. Article content Article content Article content Email: Article content pr@ Article content For investors and analysts: Article content Article content IR/SR Dept. Article content Article content Article content

CTV News
2 hours ago
- CTV News
CTV National News: Steel and aluminum tariffs doubled as Trump's trade war escalates
CTV National News: Steel and aluminum tariffs doubled as Trump's trade war escalates Prime Minister Carney is calling U.S. President Trump's doubling of steel and aluminum tariffs 'unlawful and unjustified'. Rachel Aiello has the latest.

Globe and Mail
4 hours ago
- Globe and Mail
Oil prices fall as OPEC+ boosts output, tariffs dampen outlook
Oil prices edged lower in early Asian trade on Wednesday, weighed down by a loosening supply-demand balance following increasing OPEC+ output and lingering concerns over the global economic outlook due to tariff tensions. Brent crude futures dipped 5 cents, or 0.1%, to $65.58 a barrel by 0040 GMT while U.S. West Texas Intermediate crude was at $63.32 a barrel, down 9 cents, or 0.1%. Both benchmarks climbed about 2% on Tuesday to a two-week high, supported by worries over supply disruptions from Canadian wildfires and expectations that Iran will reject a U.S. nuclear deal proposal that is key to easing sanctions on the major oil producer. 'Despite fears over Canadian supply and stalled Iran-U.S. nuclear talks, oil markets are struggling to extend gains,' said Tsuyoshi Ueno, senior economist at NLI Research Institute, adding that OPEC+ production increases were capping the upside. Ueno said hopes for progress in U.S.-China trade talks were overshadowed by profit-taking, as investors remained cautious over the broader economic fallout from tariffs. U.S. President Donald Trump and Chinese leader Xi Jinping will likely speak this week, White House press secretary Karoline Leavitt said on Monday, days after Trump accused China of violating an agreement to roll back tariffs and trade restrictions. As the Trump administration pressed U.S. trading partners to provide their best offers by Wednesday, the protracted negotiations and moving deadlines have led economists to scale back growth forecasts. On Tuesday, the Organisation for Economic Co-operation and Development cut its global growth forecast as the fallout from Trump's trade war takes a bigger toll on the U.S. economy. Meanwhile, scores of wildfires have swept across Canada since the start of May, forcing thousands of evacuations and disrupting crude oil production in the country. U.S. crude stocks fell by 3.3 million barrels in the week ended May 30, market sources said, citing American Petroleum Institute figures on Tuesday. Gasoline inventories rose by 4.7 million barrels and distillate stocks rose by about 760,000 barrels. A Reuters poll of nine analysts estimated an average draw of 1 million barrels in crude stocks. Official inventory data from the U.S. Energy Information Administration is due on Wednesday.